Skip to main content

Hormonal Treatment in Gynaecological Malignancies

  • 172 Accesses

Abstract

Hormonal therapy has an established role in the management of a selected group of women with gynaecological cancer, including endometrial and epithelial ovarian cancer, uterine sarcomas, and granulosa cell tumours. Progestin therapy has been the most widely applied hormonal treatment; notwithstanding, other agents including selective oestrogen receptor modulators, down-regulators and aromatase inhibitors are also used for treatment of advanced or recurrent disease. The rate of response to these drugs varies considerably depending upon tumour type, disease grade, stage, hormone receptors profile as well as the treatment modality used. Recently, targeted therapies, including mTOR inhibitors, have emerged as a promising treatment option, especially in combination with conventional hormonal therapy. This chapter updates the evidence for the use of hormonal therapy in women with gynaecological malignancies. Furthermore, in view of the recent advances in immunotherapy, the role of combined HT and mTOR inhibitors is also covered.

Keywords

  • Gynaecological malignancy
  • Hormonal therapy
  • Fertility sparing
  • Recurrence
  • Advanced disease

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-94110-9_12
  • Chapter length: 8 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   149.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-94110-9
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Hardcover Book
USD   199.99
Price excludes VAT (USA)

References

  1. Sommeijer DW, Sjoquist KM, Friedlander M. Hormonal treatment in recurrent and metastatic gynaecological cancers: a review of the current literature. Curr Oncol Rep. 2013;15:541–8.

    CAS  CrossRef  Google Scholar 

  2. Yu Song J, Fraser IS. Effects of progestagens on human endometrium. Obstet Gynecol Surv. 1995;50:385–94.

    CrossRef  Google Scholar 

  3. Carlson MJ, Thiel KW, Leslie KK. Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Women’s Health. 2014;6:429–35.

    Google Scholar 

  4. Jerzak KJ, Duska L, McKay HJ. Endocrine therapy in endometrial cancer: an old dog with new tricks. Gynecol Oncol. 2019;153:175–83.

    CAS  CrossRef  Google Scholar 

  5. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10–7.

    CAS  CrossRef  Google Scholar 

  6. Cancer Genome Atlas Research, Kandoth NC, Schultz N, et al. Integrated genomic characterisation go endometrial carcinoma. Nature. 2013;497:67–73.

    CrossRef  Google Scholar 

  7. Rodolakis A, Biliatis I, Morice P, Reed N, Mangler M, Kesic V, Denschlag D. European Society of Gynecological Oncology Task Force for fertility preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients. Int J Gynecol Cancer. 2015;25(7):1258–65.

    CrossRef  Google Scholar 

  8. Wei J, Zhang W, Feng L, Gao W. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia. A meta-analysis and systematic review. Medicine (Baltimore). 2017;96(37):e8034.

    CrossRef  Google Scholar 

  9. Hall C, Stone RL, Gehlot A, et al. Use of metformin in obese women with type I endometrial cancer is associated with a reduced incidence of cancer recurrence. Int J Gynecol Cancer. 2016;26:313–7.

    CrossRef  Google Scholar 

  10. Mitsuhashi A, Sato Y, Kiyokawa T, et al. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Ann Oncol. 2016;27:262–6.

    CAS  CrossRef  Google Scholar 

  11. Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer. 2016;26:2–30.

    CrossRef  Google Scholar 

  12. Martin-Hirsch PL, Jarvis G, Kitchener H, et al. Progestagens for endometrial cancer. Cochrane Database Syst Rev. 1999;4:CD001040.

    Google Scholar 

  13. Lentz SS, Brady MF, Major FJ, et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1996;14:357–61.

    CAS  CrossRef  Google Scholar 

  14. Whitney CW, Brunetto V, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:4–9.

    CAS  CrossRef  Google Scholar 

  15. Florica JV, Brunetto V, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:10–4.

    CrossRef  Google Scholar 

  16. van Weelden WJ, Massuger LFAG, Pijnenborg JMA, Romano A. Anti-estrogen treatment in endometrial cancer: a systematic review. Front Oncologia. 2019;9:359.

    CrossRef  Google Scholar 

  17. Ayoub J, Audet-Lapointe P, Methot Y, Hanley J, Beaulieu R, Chemaly R, et al. Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status. Gynecol Oncol. 1988;31:327–37.

    CAS  CrossRef  Google Scholar 

  18. Zhang G, Cheng Y, Zhang Q, Li X, Zhou J, Wang J, et al. ATX-LPA axis facilitates oestrogen-induced endometrial cancer cell proliferation via MAPK/ERK singling pathway. Mol Med Rep. 2018;17:4245–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Fleming GF, Filiaci VL, Marzullo B, Zaino RJ, Davidson SA, Pearl M, et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2014;132:585–92.

    CAS  CrossRef  Google Scholar 

  20. Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015;33:930–6.

    CAS  CrossRef  Google Scholar 

  21. Soliman PT, Westin SN, Iglesias DA, Fellman B, Yuan Y, Zhang Q, Yates M, et al. Everolimus, letrozole, and metformin in women with advanced or recurrent endometrioid endometrial cancer: a multi-center, single arm, phase II study. Clin Cancer Res. 2020;26:581–7.

    CAS  CrossRef  Google Scholar 

  22. Colon-Otero G, Zanfagnin V, Hou X, Foster NR, Asmus EJ, Hendrickson AW, Jatoi A, et al. Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. ESMO Open. 2020;5(5):e000926.

    CrossRef  Google Scholar 

  23. Leitao MM, Hensley ML, Barakat RR, Aghajanian C, Gardner CJ, Jewell EL, et al. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma. Gynecol Oncol. 2012;124:558–62.

    CAS  CrossRef  Google Scholar 

  24. George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan JA, Ramaiya N, Quek R, Penson RT, Wagner AJ, Harmon D, Demetri GD, Krasner C. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer. 2014;120:738–43.

    CAS  CrossRef  Google Scholar 

  25. Slomovitz BM, Taub MC, Huang M, Levenback C, Coleman RL. A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS) Gynecol. Oncol Rep. 2018;27:1–4.

    CrossRef  Google Scholar 

  26. Thanopoulou E, Thway K, Khabra K, Judson I. Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors. Clin Sarcoma Res. 2014;26:4–5.

    Google Scholar 

  27. Yoon A, Park JY, Park JY, Lee YY, Kim TJ, Choi CH, et al. Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: a multicenter review of 114 cases. Gynecol Oncol. 2014;2014(132):70–5.

    CrossRef  Google Scholar 

  28. Zhang YY, Li Y, Qin M, Cai Y, Jin Y, Pan LY. High-grade endometrial stromal sarcoma: a retrospective study of factors influencing prognosis. Cancer Manag Res. 2019;11:831–7.

    CrossRef  Google Scholar 

  29. Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, et al. ESMO Guidelines Committee and EURACAN. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv51–67.

    CAS  CrossRef  Google Scholar 

  30. Andersen CL, Sikora MM, Boisen MM, et al. Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens. Clin Cancer Res. 2017;23:3802–12.

    CAS  CrossRef  Google Scholar 

  31. Paleari L, Gandini S, Provinciali N, Puntoni M, Colombo N, DeCensi A. Clinical benefit and risk of death with endocrine therapy in ovarian cancer: a comprehensive review and meta-analysis. Gynecol Oncol. 2017;146:504–13.

    CrossRef  Google Scholar 

  32. Gershenson DM, Bodurka DC, Coleman RL, et al. Hormonal maintenance therapy for women with low grade serous carcinoma of the ovary or peritoneum. J Clin Oncol. 2017;35(10):1103–11.

    CrossRef  Google Scholar 

  33. Fader AN, Bergstrom J, Jernigan A, et al. Primary cytoreductive surgery and adjuvant hormonal mono therapy in women with advanced low-grade serous ovarian carcinoma: reducing over treatment without compromising survival? Gynecol Oncol. 2017;147:85–91.

    CAS  CrossRef  Google Scholar 

  34. Farinola MA, Gown AM, Judson K, et al. Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors. Int J Gynecol Pathol. 2007;26:375–82.

    CrossRef  Google Scholar 

  35. van Meurs HS, van Lonkhuijzen LRCW, Limpens J, van der Velden J, Buist MR. Hormone therapy in ovarian granulosa cell tumors: a systematic review. Gynecol Oncol. 2014;134:196–205.

    CrossRef  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anastasios Tranoulis .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Tranoulis, A., Fernando, I.N. (2022). Hormonal Treatment in Gynaecological Malignancies. In: Singh, K., Gupta, B. (eds) Gynecological Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-94110-9_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-94110-9_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-94109-3

  • Online ISBN: 978-3-030-94110-9

  • eBook Packages: MedicineMedicine (R0)